Candesant Biomedical Announces $35M in Series B Financing to Advance Commercialization of Brella™, the First and Only FDA-cleared 3-Minute SweatControl Patch™
/PRNewswire/ -- Candesant Biomedical, Inc. ("Candesant"), a private medical device company focused on the development and commercialization of non-invasive...
United States Suzanne Haber Candesant Biomedical Inc Prnewswire Candesant Biomedical Inc Brella Early Experience Program Consumer Survey On Cosmetic Dermatologic Procedures
Source: prnewswire.com